2-(2-甲基苯基)喹啉-4-羧酸 | 174636-85-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 2-(2-甲基苯基)喹啉-4-羧酸
• 中文别名: 喹啉-4-羧酸,2-(2-甲基苯基)-
• 英文名称: 2-(o-methylphenyl)quinoline-4-carboxylic acid
• 英文别名: 2-(2'-methylphenyl)quinoline-4-carboxylic acid；2-(2-Methylphenyl)quinoline-4-carboxylic acid
• CAS: 174636-85-2
• 化学式: C₁₇H₁₃NO₂
• mdl: MFCD01114911
• 分子量: 263.296
• InChiKey: YLQGICXPTGQXFS-UHFFFAOYSA-N

物化性质

• 熔点：
  >220°C (dec.)
• 沸点：
  447.1±33.0 °C(Predicted)
• 密度：
  1.248±0.06 g/cm3(Predicted)
• 溶解度：
  DMSO（少量）、甲醇（轻微、超声处理）

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  2-(2-甲基苯基)喹啉-4-羧酸 在 吡啶 、 氯化亚砜 作用下， 生成 2-(2-methylphenyl)-N-{4-[(4-methylpyrimidin-2-yl)sulfamoyl]phenyl}quinoline-4-carboxamide
  参考文献：
  名称：

  Discovering novel chemical inhibitors of human cyclophilin A: Virtual screening, synthesis, and bioassay

  摘要：

  Cyclophilin A (CypA) is a member of cyclophilins, a family of the highly homologous peptidyl prolyl cis-trans isomerases (PPIases), which can bind to cyclosporin A (CsA). CypA plays critical roles in various biological processes, including protein folding, assembly, transportation, regulation of neuron growth, and HIV replication. The discovery of CypA inhibitor is now of a great special interest in the treatment of immunological disorders. In this study, a series of novel small molecular CypA inhibitors have been discovered by using structure-based virtual screening in conjunction with chemical synthesis and bioassay. The SPECS-1 database containing 85,000 small molecular compounds was searched by virtual screening against the crystal structure of human CypA. After SPR-based binding affinity assay, 15 compounds were found to show binding affinities to CypA at submicro-molar or micromolar level (compounds 1-15). Seven compounds were selected as the starting point for the further structure modification in considering binding activity, synthesis difficulty, and structure similarity. We thus synthesized 40 new small molecular compounds (1-6, 15, 16a-q, 17a-d, and 18a-I), and four of which (compounds 16b, 16h 16k,. and 18g) showed high CypA PPIase inhibition activities with IC50S of 2.5-6,2 mu M. Pharmacological assay indicated that these four Compounds demonstrated somewhat inhibition activities against the proliferation of spleen cells. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.11.006
• 作为产物：
  描述：

  2-羟基亚氨基-n-苯乙酰胺 在 硫酸 、 potassium hydroxide 作用下， 以 乙醇 为溶剂， 生成 2-(2-甲基苯基)喹啉-4-羧酸
  参考文献：
  名称：

  新型微管蛋白聚合抑制剂2-苯基喹啉-4-羧酰胺衍生物的设计，合成及生物学评价

  摘要：

  合成，表征和评估了一系列新的2-苯基喹啉-4-羧酰胺衍生物对五种癌细胞系（Hela，SK-OV-3，HCT116，A549和MDA-MB-468）和正常人的抗增殖活性胎儿肺成纤维细胞系，MRC-5。其中，化合物7b在体外显示出对SK-OV-3和HCT116细胞系的有效细胞毒活性，IC 50值分别为0.5和0.2μM。通常，抗增殖活性与秋水仙碱结合位点的结合特性和对微管蛋白聚合的抑制作用有关。此外，免疫荧光和流式细胞仪分析表明，选定的化合物导致有丝分裂纺锤体装配和G 2的破坏细胞周期的/ M期停滞，与增殖抑制活性有关。分子对接分析表明7b在微管蛋白的秋水仙碱结合位点相互作用。这些结果表明这些化合物是用于有效治疗癌症的微管蛋白聚合的有希望的抑制剂。

  DOI：

  10.1016/j.bmc.2017.09.004

文献信息

• 一种ACC抑制剂及其医药用途
  申请人：徐州医科大学

  公开号：CN111574530B

  公开（公告）日：2022-07-26

  本发明涉及一种ACC抑制剂及其医药用途，属于药物化学和药物治疗学领域。本发明提供的式I所示的化合物、异构体或其药学上可接受的盐，不仅对ACC具有良好的酶活，同时具有良好的抗肿瘤活性，可应用在抗肿瘤药物的制备中，特别是在抗肺癌、抗肝癌或抗乳腺癌药物中具有优异的应用前景。
• Discovery of a Novel Class of Selective Non-Peptide Antagonists for the Human Neurokinin-3 Receptor. 1. Identification of the 4-Quinolinecarboxamide Framework
  作者：Giuseppe A. M. Giardina、Henry M. Sarau、Carlo Farina、Andrew D. Medhurst、Mario Grugni、Luca F. Raveglia、Dulcie B. Schmidt、Roberto Rigolio、Mark Luttmann、Vittorio Vecchietti、Douglas W. P. Hay

  DOI：10.1021/jm960818o

  日期：1997.6.1

  A novel class of potent and selective non-peptide neurokinin-3 (NK-3) receptor antagonists, featuring the 4-quinolinecarboxamide framework, has been designed based upon chemically diverse NK-1 receptor antagonists. The novel compounds 33-76, prompted by chemical modifications of the prototype 4, have been characterized by binding analysis using a membrane preparation of chinese hamster ovary (CHO)

  基于化学上不同的NK-1受体拮抗剂，设计了一种新型的有效且选择性的非肽神经激肽3（NK-3）受体拮抗剂，其特征在于4-喹啉羧酰胺骨架。通过原型4的化学修饰促进了新型化合物33-76的表达，其特征在于使用表达人神经激肽3受体（hNK-3-CHO）的中国仓鼠卵巢（CHO）细胞膜制剂进行结合分析，并建立了明确的结构-活性关系（SAR）。从SARs（R）-N- [α-（甲氧基羰基）苄基] -2-苯基喹啉-4-羧酰胺（65，SB 218795，hNK-3-CHO结合Ki = 13 nM）出现，是最有效的化合物之一这个新颖的班级。对其他神经激肽受体（hNK-2-CHO和hNK-1-CHO）的选择性研究表明，对hNK-3的选择性是对hNK-2受体的65倍（hNK-2-CHO结合Ki = 1221 nM）。相对于hNK-1受体具有超过7000倍的选择性（hNK-1-CHO结合Ki => 100 micro
• Quinoline-4-carbonylguanidine derivatives, process for producing the
  申请人：Mitsui Toatsu Chemicals, Inc.

  公开号：US05627193A1

  公开（公告）日：1997-05-06

  The present invention relates to quinoline-4-carbonylguanidine derivative represented by formula (1) ##STR1## and pharmaceutically acceptable salt thereof, a process for producing the same, and a Na.sup.+ /H.sup.+ exchanger inhibitor containing the compound as an active ingredient. The compounds of the present invention are useful as an agent for treating or preventing various diseases by hyperfunction of the Na.sup.+ /H.sup.+ exchanger and as a diagnostic agent for these diseases.

  本发明涉及由式（1）所代表的喹啉-4-羰基胍衍生物及其药学上可接受的盐，制备该化合物的方法，以及含有该化合物作为活性成分的Na.sup.+ /H.sup.+交换抑制剂。本发明的化合物可用作治疗或预防由Na.sup.+ /H.sup.+交换器的高功能引起的各种疾病的药剂，以及用于这些疾病的诊断剂。
• Synthesis and in vitro evaluation of novel spiroketopyrazoles as acetyl-CoA carboxylase inhibitors and potential antitumor agents
  作者：Tonghui Huang、Xin Wu、Shirong Yan、Tianya Liu、Xiaoxing Yin

  DOI：10.1016/j.ejmech.2020.113036

  日期：2021.2

  and survival of cancer cells. In this study, a series of spiroketopyrazole derivatives bearing quinoline moieties were synthesized, and in vitro anticancer activities of these compounds as ACC inhibitors were evaluated. The biological evaluation showed that compound 7j exhibited the strongest enzyme inhibitory activity (IC50 = 1.29 nM), while compound 7m displayed the most potent anti-proliferative activity

  乙酰辅酶A羧化酶（ACC）是从头脂肪酸合成中的限速酶，在癌细胞的生长和存活中起关键作用。在这项研究中，合成了一系列带有喹啉部分的螺并吡咯衍生物，并评估了这些化合物作为ACC抑制剂的体外抗癌活性。生物学评估表明，化合物7j表现出最强的酶抑制活性（IC 50 = 1.29 nM），而化合物7m对具有相应IC 50的A549，HepG2和MDA-MB-231细胞表现出最强的抗增殖活性。值分别为0.55、0.38和1.65μM。初步的药理研究证实，化合物7m以剂量依赖性方式降低细胞内丙二酰辅酶A和TG的水平。此外，它可能下调细胞周期蛋白D1和CDK4干扰细胞周期并上调Bax，caspase-3和PARP，同时抑制Bcl-2诱导细胞凋亡。值得注意的是，7m与阿霉素的组合协同降低了HepG2细胞的活力。这些结果表明，化合物7m作为单一药物或与其他抗肿瘤药物联合使用，可能是治疗肝细胞癌的有前途的治疗药物。
• Synthesis, Biological Evaluation and Molecular Docking Studies of Piperidinylpiperidines and Spirochromanones Possessing Quinoline Moieties as Acetyl-CoA Carboxylase Inhibitors
  作者：Tonghui Huang、Jie Sun、Qianqian Wang、Jian Gao、Yi Liu

  DOI：10.3390/molecules200916221

  日期：——

  against obesity, diabetes and other metabolic diseases. Two series of compounds possessing quinoline moieties were designed, synthesized and evaluated for their potential to inhibit acetyl-CoA carboxylases. Most compounds showed moderate to good ACC inhibitory activities and compound 7a possessed the most potent biological activities against ACC1 and ACC2, with IC50 values of 189 nM and 172 nM, respectively

  乙酰辅酶 A 羧化酶 (ACCs) 在脂肪酸代谢的调节中起关键作用，并已成为开发针对肥胖、糖尿病和其他代谢疾病的药物的目标。设计、合成了具有喹啉部分的两个系列化合物，并评估了它们抑制乙酰辅酶 A 羧化酶的潜力。大多数化合物显示出中等至良好的 ACC 抑制活性，化合物 7a 对 ACC1 和 ACC2 具有最有效的生物活性，IC50 值分别为 189 nM 和 172 nM，与阳性对照相当。进行对接模拟以将化合物 7a 定位到 ACC 的活性位点以确定可能的结合模型。